Is Enveric Biosciences going out of business?

Enveric Biosciences, Inc. (ENVB) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Enveric Biosciences, Inc. (ENVB) scores 15 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: Reverse split detected; adjusted share change (25.2% YoY) and the capital-structure risk is penalized.

Five questions, kept separate

Survival - Fragile

Runway cannot be estimated from the available cash and cash-flow fields. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

215.8% burn burden support an extreme expectations pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: Reverse split detected; adjusted share change (25.2% YoY) and the capital-structure risk is penalized.
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -98.08%
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-14.

Price as of 2026-09-09.